Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Pre-, During- and Post-HSCT for Myelofibrosis
NCT03427866Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), sponsored by Massachusetts General Hospital. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03427866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427866.